Infectologia

Vídeo | Pílula da Merck contra a Covid transforma o tratamento. É assim que ela funciona.

14 Out, 2021 | 10:48h

Watch: Merck’s Covid pill could transform treatment. Here’s how it works – STAT

Conteúdos relacionados:

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

---

OMS recomenda a aplicação da 3ª dose da vacina contra COVID em grupos de mais alto risco.

13 Out, 2021 | 13:43h

WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups – CIDRAP

Ver também: WHO advises additional COVID shot for immunocompromised people – Reuters

---

Opinião | Lição da COVID: confie no público com verdades concretas.

13 Out, 2021 | 13:42h

COVID lesson: trust the public with hard truths – Nature

 

Comentário do autor no Twitter (fio – clique para saber mais)

Today in @Nature, I outline a key lesson from COVID-19:

"Governments, dare to to trust your citizens."

Governments' fear of their people is not supported by science & it stymies pandemic management and breeds vaccine hesitancy.

Read it here: https://t.co/dbr5Epggow.

🧵 (1/8) pic.twitter.com/EegEIxGb2r

— Michael Bang Petersen (@M_B_Petersen) October 12, 2021

 

---

Uma cartilha sobre o que se sabe a respeito de misturar e combinar vacinas contra Covid.

13 Out, 2021 | 13:40h

A primer on what we know about mixing and matching Covid vaccines – STAT

Conteúdos relacionados:

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

---

Dados de vida real mostram que filtros eliminam do ar o vírus causador da COVID.

13 Out, 2021 | 13:39h

Real-world data show that filters clean COVID-causing virus from air – Nature

Artigo original: The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units – medRxiv

 

Comentário no Twitter

Research at a hospital swamped by people with COVID-19 has confirmed that portable air filters effectively remove SARS-CoV-2 particles from the air https://t.co/OT3JKIxWhB

— nature (@Nature) October 11, 2021

 

---

Soroconversão e febre são fatores dose-dependentes em um modelo primata não humano de COVID-19 inalatória.

13 Out, 2021 | 13:37h

Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19 – PLOS Pathogens

Comentário: Dose-dependent COVID-19 symptoms – Nature Reviews Microbiology

 

Comentários no Twitter

When exposed to #SARSCoV2 why does one person have no illness, while another is soon in ICU?
Dose.
Controlled study in monkeys shows the dose of viruses inhaled is a key factor determining the severity of the disease.
Seems obvious, yet this is new.https://t.co/zdfCnR40bR pic.twitter.com/HH8kxMM2xm

— Laurie Garrett (@Laurie_Garrett) October 11, 2021

In summer of 2020, our group had proposed a hypothesis that SARS-CoV-2 viral dose or "inoculum" was associated with severity of symptoms in COVID (and proposed NPIs reduced the dose). There is now an experimental model showing this in cynomolgus monkeys:https://t.co/dXGDPyPBFZ

— Monica Gandhi MD, MPH (@MonicaGandhi9) October 12, 2021

 

---

M-A | Frequência de manifestações neurológicas na COVID-19: até 1/3 dos pacientes (89% internados) vivenciaram pelo menos 1 manifestação neurológica.

13 Out, 2021 | 13:36h

Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis – Neurology

---

Estudo randomizado | Não há benefício da terapia antitrombótica (aspirina ou apixabam) para pacientes ambulatoriais com COVID-19 sintomática clinicamente estáveis.

13 Out, 2021 | 12:56h

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA

Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA

 

Comentário no Twitter

Data do not support the use of aspirin or apixaban in the outpatient setting to reduce the major adverse cardiovascular or pulmonary consequences associated with symptomatic but clinically stable #SARSCoV2 infection https://t.co/SH6OefXOCj #COVID19

— JAMA (@JAMA_current) October 11, 2021

 

---

Teste do D-dímero para excluir embolia pulmonar tem utilidade clínica limitada em pacientes internados com COVID-19 – A maioria dos pacientes, com ou sem embolia pulmonar, apresenta níveis elevados.

13 Out, 2021 | 12:54h

D-Dimer Testing for the Exclusion of Pulmonary Embolism Among Hospitalized Patients With COVID-19 – JAMA Network Open

Comentário: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay

---

Estudo nacional na Suécia mostra ligação entre vacinação contra COVID e redução na transmissão domiciliar.

13 Out, 2021 | 12:53h

Comunicado de imprensa: Nationwide study shows link between COVID vaccination and reduced household transmission – Umea University

Estudo original: Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members – JAMA Internal Medicine

Conteúdos relacionados:

Review | Prevention of host-to-host transmission by SARS-CoV-2 vaccines.

Study ties COVID vaccines to lower transmission rates.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

---